IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

IN RE: INVOKANA (CANAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION	: MDL NO. 2750 : JUDGE BRIAN R. MARTINOTTI : JUDGE LOIS H. GOODMAN :
Document Relates to [INSERT CASE NAME A	AND NUMBER]
INJURY PROFILE FORM: 1	DIABETIC KETOACIDOSIS
Name:	DOB:
Plaintiff's Firm:	SSN:
Date of 1st Invokana Use:	Bates/Page # ² :
Date(s) of DKA event:	Bates/Page #:
Did Plaintiff's DKA event occur prior to December 4 ☐ Yes. ☐ No.	, 2015?
Please confirm that Plaintiff was taking Invokana as ptime of his/her DKA event: \[\subseteq \text{Yes, Plaintiff was taking Invokana as prestime of the DKA event.} \] \[\subseteq \text{No.} \]	
Please identify the type of records Plaintiff has submi proof of Plaintiff's Invokana use and proof of Plaintif ☐ Pharmacy ☐ Hospital ☐ Prescriber	f's diabetic ketoacidosis event:
[Continued to	o Next Page]

¹ "Invokana" is defined to include Invokana, Invokamet and Invokamet XR.

² In lieu of providing a Bates reference, Plaintiff may provide either: (a) a reference to the relevant PDF and PDF page number; or (b) annotated versions of the records produced with highlighting, annotation or bookmarks calling out the relevant information.

Records Produced Supporting Invokana Use
☐ Pharmacy, insurance, prescriber records, or patient assistance program records showing patient was prescribed Invokana (Bates/Page #:);
☐ Pharmacy, insurance, hospital records, or patient assistance program records showing use of Invokana at to the time of the DKA event <i>or</i> proof that Plaintiff had and was taking Invokana samples at the time of the DKA event (Bates/Page #:);
<u>Diabetes Type</u> : ☐ Type 1 Diabetes ☐ Type 2 Diabetes (Bates/Page #:)
☐ Pharmacy records documenting an actual fill of an Invokana prescription in the 4-week period prior to Plaintiff's DKA event (or 12-week period, for a 90-day prescription), or proof that Plaintiff was taking Invokana samples at the time of the DKA event (Bates/Page #:)
Records Produced Supporting DKA Event
☐ Confirmed DKA diagnosis (Bates/Page #:)
☐ Identify the relevant serum pH values here:(Bates/Page #:)
☐ Identify the relevant CO2/HCO3 values here: (Bates/Page #:)
☐ Identify the relevant anion gap values here: (Bates/Page #:)
Identify the relevant serum ketones values (β-hydroxybutrate or acetone) here: (Bates/Page #:)
☐ Identify the relevant urine ketones values here:
Severity of Injury
Length of hospitalization: \Box 1-2 days \Box 3-4 days \Box 5-6 days \Box 7+ days \Box 20+ days
☐ Encephalopathy (dates):(Bates/Page #:)
☐ Respiratory failure w/ intubation (dates): (Bates/Page #:)
Dialysis (dates):(Bates/Page #:)
☐ Acute kidney injury / renal failure (dates):(Bates/Page #:)
☐ DKA-related death (death certificate <u>must</u> be produced).

Medical Condition at Time of DKA Event

☐ Underlying infection or illness:	
(Bates/Page #:)	
☐ Major trauma, surgery, or cardiovascular ever	nt in week prior to DKA event (type and dates):
= 1. Light transition, our gory, or our area value or or	(Jpc and autos).
(Bates/Page #:)	
☐ Chronic alcohol abuse:	(Bates/Page #:)
☐ Chronic drug abuse:	(Bates/Page #:)
☐ Strenuous physical activity or exercise preced	ling DKA:
(Bates/Page #:)	
	FESTATION pleted this Injury Profile Form in good faith.
Date:	[INSERT PLAINTIFF NAME]
Date:	[INSERT ATTORNEY NAME & FIRM